H M Crauwels1, O Osiyemi2, C Zorrilla3, C Bicer4, K Brown5. 1. Janssen Research & Development, Beerse, Belgium. 2. Triple O Research Institute PA, West Palm Beach, FL, USA. 3. University of Puerto Rico School of Medicine, San Juan, Puerto Rico. 4. BICER Consulting & Research, Antwerp, Belgium. 5. Janssen Research & Development, LLC, Titusville, NJ, USA.
Abstract
OBJECTIVES: The aim of the study was to evaluate darunavir and cobicistat pharmacokinetics in pregnant women with HIV-1 infection. METHODS: This phase 3b, open-label study enrolled HIV-1-infected pregnant women (18-26 weeks of gestation) receiving combination antiretroviral therapy with once-daily darunavir/cobicistat 800/150 mg. The plasma pharmacokinetics of darunavir (total and unbound) and cobicistat were assessed over 24 h during the second and third trimesters (24-28 and 34-38 weeks of gestation, respectively) and 6-12 weeks postpartum. Pharmacokinetic parameters [area under the plasma concentration-time curve over 24 h (AUC24 h ), maximum plasma concentration (Cmax ) and minimum plasma concentration (Cmin )] were derived using noncompartmental analysis and compared using linear mixed effects modelling (pregnancy versus postpartum). Antiviral activity and safety were evaluated. RESULTS: Seven women were enrolled in the study; six completed it. Total darunavir exposure was lower during pregnancy than postpartum (AUC24 h , 50-56% lower; Cmax , 37-49% lower; Cmin , 89-92% lower); unbound darunavir exposure was also reduced (AUC24 h , 40-45% lower; Cmax , 32-41% lower; Cmin , 88-92% lower). Cobicistat exposure was also lower during pregnancy than postpartum (AUC24 h , 49-63% lower; Cmax , 27-50% lower; Cmin , 83% lower). At study completion, five of six (83%) women were virologically suppressed (HIV-1 RNA < 50 copies/mL). There was one virological failure (the patient was nonadherent; no emerging genotypic resistance was observed and susceptibility to antiretrovirals was maintained). No mother-to-child transmission was detected among six infants born to the six women who completed the study. Overall, darunavir/cobicistat was well tolerated in women and infants. CONCLUSIONS: In view of markedly reduced darunavir and cobicistat exposures during pregnancy, this combination is not recommended in HIV-1-infected pregnant women.
OBJECTIVES: The aim of the study was to evaluate darunavir and cobicistat pharmacokinetics in pregnant women with HIV-1 infection. METHODS: This phase 3b, open-label study enrolled HIV-1-infected pregnant women (18-26 weeks of gestation) receiving combination antiretroviral therapy with once-daily darunavir/cobicistat 800/150 mg. The plasma pharmacokinetics of darunavir (total and unbound) and cobicistat were assessed over 24 h during the second and third trimesters (24-28 and 34-38 weeks of gestation, respectively) and 6-12 weeks postpartum. Pharmacokinetic parameters [area under the plasma concentration-time curve over 24 h (AUC24 h ), maximum plasma concentration (Cmax ) and minimum plasma concentration (Cmin )] were derived using noncompartmental analysis and compared using linear mixed effects modelling (pregnancy versus postpartum). Antiviral activity and safety were evaluated. RESULTS: Seven women were enrolled in the study; six completed it. Total darunavir exposure was lower during pregnancy than postpartum (AUC24 h , 50-56% lower; Cmax , 37-49% lower; Cmin , 89-92% lower); unbound darunavir exposure was also reduced (AUC24 h , 40-45% lower; Cmax , 32-41% lower; Cmin , 88-92% lower). Cobicistat exposure was also lower during pregnancy than postpartum (AUC24 h , 49-63% lower; Cmax , 27-50% lower; Cmin , 83% lower). At study completion, five of six (83%) women were virologically suppressed (HIV-1 RNA < 50 copies/mL). There was one virological failure (the patient was nonadherent; no emerging genotypic resistance was observed and susceptibility to antiretrovirals was maintained). No mother-to-child transmission was detected among six infants born to the six women who completed the study. Overall, darunavir/cobicistat was well tolerated in women and infants. CONCLUSIONS: In view of markedly reduced darunavir and cobicistat exposures during pregnancy, this combination is not recommended in HIV-1-infected pregnant women.
Authors: Jeremiah D Momper; Jiajia Wang; Alice Stek; David E Shapiro; Kathleen M Powis; Mary E Paul; Martina L Badell; Renee Browning; Nahida Chakhtoura; Kayla Denson; Kittipong Rungruengthanakit; Kathleen George; Edmund V Capparelli; Mark Mirochnick; Brookie M Best Journal: J Acquir Immune Defic Syndr Date: 2022-03-01 Impact factor: 3.771
Authors: Kristina M Brooks; Jeremiah D Momper; Mauricio Pinilla; Alice M Stek; Emily Barr; Adriana Weinberg; Jaime G Deville; Irma L Febo; Mikhaela Cielo; Kathleen George; Kayla Denson; Kittipong Rungruengthanakit; David E Shapiro; Elizabeth Smith; Nahida Chakhtoura; James F Rooney; Richard Haubrich; Rowena Espina; Edmund V Capparelli; Mark Mirochnick; Brookie M Best Journal: AIDS Date: 2021-03-01 Impact factor: 4.177
Authors: Jeremiah D Momper; Jiajia Wang; Alice Stek; David E Shapiro; Gwendolyn B Scott; Mary E Paul; Irma L Febo; Sandra Burchett; Elizabeth Smith; Nahida Chakhtoura; Kayla Denson; Kittipong Rungruengthanakit; Kathleen George; Derek Z Yang; Edmund V Capparelli; Mark Mirochnick; Brookie M Best Journal: AIDS Date: 2021-07-01 Impact factor: 4.632
Authors: Ahizechukwu C Eke; Adeniyi Olagunju; Brookie M Best; Mark Mirochnick; Jeremiah D Momper; Elaine Abrams; Martina Penazzato; Tim R Cressey; Angela Colbers Journal: Clin Pharmacokinet Date: 2020-10 Impact factor: 6.447